Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study
Digestive Diseases · 2025
DOI: 10.1159/000547994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases, 2025. Verfasst von Miguel Regueiro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Dose escalation with biologics is common among patients with ulcerative colitis (UC). We investigated the dose escalation and associated incremental costs among patients treated with biologics for UC.
Methods
This study utilized the Merative™ MarketScan® database in the USA to identify adults with at least two claims for UC and at least two refill/infusion claims for maintenance doses of biologics (including adalimumab, infliximab, ustekinumab, and vedolizumab) from January 1, 2015, to December 31, 2022. Patients were stratified by the presence (bio-experienced) or absence (bio-naïve) of other advanced therapy claims during the baseline period (12 months before index date). Descriptive statistics were used to summarize the dose escalation measures (frequency and magnitude of dose escalation, incremental cost due to dose escalation, and time-to-first dose escalation).
Results
Of 1,812 patients with UC who were on biologics during the maintenance phase, 56.3% had dose escalation. Overall, magnitude of dose escalation was 119.9% adalimumab, 34.9% infliximab, 81.6% ustekinumab, and 55.4% vedolizumab. Overall, median time-to-first dose escalation after initiating maintenance therapy ranged from nearly a month to 5 months (adalimumab: 0.8, infliximab: 5.1, ustekinumab: 1.3, and vedolizumab: 5.1). Estimated incremental annual cost per patient incurred due to dose escalation in US dollars was USD 37,359 for adalimumab (bio-naïve: USD 36,367; bio-experienced: USD 44,180) and USD 73,765 for ustekinumab (bio-naïve: USD 74,554; bio-experienced: USD 73,599).
Conclusions
Dose escalation with biologics for UC in the USA is common. This practice has substantially increased the average medication cost of biologics to payers/patients compared to their approved doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, Cleveland, Ohio, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
Zitieren
APA
Regueiro, M., Gulati, T., Bandyopadhyay, A., Fisher, D. A., Moses, R., Creveling, T., Jha, P., & Upadhyay, N. (2025). Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study. Digestive Diseases. https://doi.org/10.1159/000547994
Vancouver
Regueiro M, Gulati T, Bandyopadhyay A, Fisher DA, Moses R, Creveling T, et al. Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study. Digestive Diseases. 2025. doi:10.1159/000547994
BibTeX
@article{Regueiro2025,
author = {Regueiro, Miguel and Gulati, Tania and Bandyopadhyay, Ashmita and Fisher, Deborah A and Moses, Richard and Creveling, Thomas and Jha, Payal and Upadhyay, Navneet},
title = {Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study},
journal = {Digestive Diseases},
year = {2025},
doi = {10.1159/000547994}
}
EUVIMED